INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
HOUSE PTR/PurchaseVerified data

Gilbert Ray Cisneros, Jr. bought PCVX

Self · Vaxcyte, Inc. · Vaxcyte, Inc. - Common Stock

Side
BUY
Value range
$1,001 – $15K
Shares
Not disclosed
Price
—
Executed
May 12, 2026
Disclosed
Jun 8, 2026
Disclosure timeline27 days from execution to publication · legal deadline 45 days
May 12 executedJun 8, 2026 disclosed

PCVX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type+14 / 20

    Purchase

  • Relative size+2 / 25

    Disclosed range starting at $1K

  • Filing timing0 / 15

    Disclosed 27 days after execution (STOCK Act deadline: 45)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PCVX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$78K
    3,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    2,250 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    6
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$21K
    343 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$116K
    1,907 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$12K
    2,250 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    3,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    3
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$36K
    586 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$147K
    2,414 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.56M
    18.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    7
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    18.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    2
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$96K
    18.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    10
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M$492K
    19.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    20
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.65M
    19.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Option exercise · 10b5-1 plan
    		M—
    19.0K sh
    		Oct 5, 2026Oct 7, 2026
    traded Oct 5, 2026
    		+2dSEC FORM 4

    Evidence

    26
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale
    		SELL$84K
    1,381 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    9
    CE
    Cowan ElviaSVP, Finance & CAO
    PCVXVaxcyte, Inc.
    Tax withholding
    		F$80K
    1,327 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    11
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Tax withholding
    		F$330K
    5,459 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    15
    DS
    Dhaliwal Harpreet S.Chief Technical Ops Officer
    PCVXVaxcyte, Inc.
    Tax withholding
    		F$462K
    7,651 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    15
    JL
    Jodar LuisChief Medical Officer
    PCVXVaxcyte, Inc.
    Grant or award
    		A—
    88.3K sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    20
    WJ
    Wassil JimEVP, Chief Scientific Ofc, COO
    PCVXVaxcyte, Inc.
    Open-market sale
    		SELL$79K
    1,334 sh
    		Sep 9, 2026Sep 9, 2026
    traded Sep 9, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20034713

    Timestamps

    Event (reported)
    May 12, 2026
    Published
    Jun 8, 2026
    Ingested by INSIDER
    Nov 5, 00:34 UTC
    Last re-read
    Nov 5, 06:47 UTC

    Extracted facts

    Filer
    Gilbert Ray Cisneros, Jr.
    Role
    Self
    Transaction
    PurchaseAs filed: “P”
    Asset
    Vaxcyte, Inc. - Common Stock
    Ticker
    PCVX
    Reported value
    $1,001 – $15KAs filed: “$1,001 - $15,000”
    Execution date (reported)
    May 12, 2026
    Notification date (reported)
    Jun 5, 2026
    Days from execution to publication
    27

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $1,001
    • High: $15,000

    = $8,001

    What this establishes

    Gilbert Ray Cisneros, Jr. reported a purchase of Vaxcyte, Inc. - Common Stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Self
    Gilbert Ray Cisneros, Jr.bioguide:C001123
    Issuer
    Vaxcyte, Inc.cik:0001649094

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.